A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

Abroad (travel likely)RecruitingPHASE3

Conditions

Triple Negative Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Columbus Regional Research Institute, LLC, Columbus, Georgia, United States
Contact: Study coordinator (Heather Wicker) · 706-780-6201
Contact: Principal Investigator (Andrew Pippas, MD)
Cox Medical Center, Springfield, Missouri, United States
Contact: Study coordinator (Anna Young) · (417) 269-7107
Contact: Principal Investigator (Srikant Nannapaneni, MD)
Gabrail Cancer Center, Canton, Ohio, United States
Contact: Study coordinator (Carrie Smith, RN) · csmith@gabrialcancercenter.com
Contact: Principal Investigator (Nashat Gabrail, MD)
Kailash Cancer Hospital & Research Centre, Vadodara, Gujarat, India
Contact: Study coordinator (Rakshit Shah) · rakshit.shah@greenashram.org · +919913771374

Study leads

Dr. Ravi Alamchandani
Study Chair
Lambda Therapeutic Research Ltd.

View source on ClinicalTrials.gov Contact study team (email)